James Blome Sells 3,495 Shares of Calyxt Inc (NASDAQ:CLXT) Stock

Share on StockTwits

Calyxt Inc (NASDAQ:CLXT) CEO James Blome sold 3,495 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.65, for a total value of $16,251.75. Following the completion of the transaction, the chief executive officer now owns 198,057 shares in the company, valued at approximately $920,965.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

James Blome also recently made the following trade(s):

  • On Monday, June 29th, James Blome sold 2,902 shares of Calyxt stock. The stock was sold at an average price of $5.01, for a total value of $14,539.02.

CLXT opened at $4.41 on Friday. Calyxt Inc has a 1-year low of $2.40 and a 1-year high of $9.77. The company has a debt-to-equity ratio of 0.35, a current ratio of 9.38 and a quick ratio of 8.80. The business has a 50 day moving average of $4.90 and a 200-day moving average of $4.85.

Calyxt (NASDAQ:CLXT) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Calyxt had a negative net margin of 455.07% and a negative return on equity of 64.78%. The business had revenue of $2.38 million during the quarter. Equities research analysts predict that Calyxt Inc will post -1.22 earnings per share for the current fiscal year.

CLXT has been the topic of a number of research reports. Zacks Investment Research downgraded Calyxt from a “buy” rating to a “hold” rating in a report on Monday, June 8th. Wells Fargo & Co decreased their target price on Calyxt from $6.00 to $4.00 and set an “equal weight” rating for the company in a research report on Friday, May 15th. Canaccord Genuity started coverage on Calyxt in a research report on Tuesday, July 28th. They set a “buy” rating and a $8.00 target price for the company. BMO Capital Markets cut Calyxt from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $13.00 to $7.00 in a research report on Friday, May 8th. Finally, National Securities reaffirmed a “buy” rating and set a $10.00 target price on shares of Calyxt in a research report on Friday, May 8th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $6.88.

Institutional investors and hedge funds have recently bought and sold shares of the company. Oppenheimer & Co. Inc. bought a new position in Calyxt in the first quarter worth $47,000. Two Sigma Investments LP bought a new position in Calyxt in the first quarter worth $61,000. Bank of New York Mellon Corp lifted its position in Calyxt by 15.8% in the first quarter. Bank of New York Mellon Corp now owns 26,097 shares of the company’s stock worth $86,000 after purchasing an additional 3,563 shares during the period. UBS Group AG lifted its position in Calyxt by 40.4% in the fourth quarter. UBS Group AG now owns 14,296 shares of the company’s stock worth $100,000 after purchasing an additional 4,116 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Calyxt by 26.9% in the first quarter. Wells Fargo & Company MN now owns 45,933 shares of the company’s stock worth $153,000 after purchasing an additional 9,733 shares during the period. 23.93% of the stock is owned by institutional investors.

About Calyxt

Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes.

See Also: CD Ladder

Insider Buying and Selling by Quarter for Calyxt (NASDAQ:CLXT)

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Buying: Tristate Capital Holdings Inc  Director Buys $13,730.00 in Stock
Insider Buying: Tristate Capital Holdings Inc Director Buys $13,730.00 in Stock
Sigmaroc’s  Buy Rating Reiterated at Liberum Capital
Sigmaroc’s Buy Rating Reiterated at Liberum Capital
Gregory B. Morrison Acquires 913 Shares of Veritex Holdings Inc  Stock
Gregory B. Morrison Acquires 913 Shares of Veritex Holdings Inc Stock
Brian Choi Buys 2,311 Shares of Op Bancorp  Stock
Brian Choi Buys 2,311 Shares of Op Bancorp Stock
Donald J. Straka Buys 1,000 Shares of Great Western Bancorp Inc  Stock
Donald J. Straka Buys 1,000 Shares of Great Western Bancorp Inc Stock
Gary C. Allerheiligen Purchases 1,000 Shares of Equity BancShares Inc  Stock
Gary C. Allerheiligen Purchases 1,000 Shares of Equity BancShares Inc Stock


© 2006-2020 Ticker Report